Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Heidelberg Pharma AG    WL6   DE000A11QVV0

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Heidelberg Pharma AG : Notification and public disclosure of transactions by persons

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 04:30pm CET


Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

10.11.2017 / 16:28
The issuer is solely responsible for the content of this announcement.


1. Details of the person discharging managerial responsibilities / person closely associated

a) Name
Name and legal form: NewMarket Venture Verwaltungs GmbH

2. Reason for the notification

a) Position / status
Person closely associated with:
Title: Prof. Dr.
First name: Christof
Last name(s): Hettich
Position: Member of the administrative or supervisory body

b) Initial notification

3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name
Heidelberg Pharma AG

b) LEI
391200E09XYBYITR1W32 

4. Details of the transaction(s)

a) Description of the financial instrument, type of instrument, identification code
Type: Derivative
ISIN: DE000A2GSZB8

b) Nature of the transaction
Granting of 40,141 subscription rights within a capital increase

c) Price(s) and volume(s)
Price(s) Volume(s)
0 EUR 0 EUR

d) Aggregated information
Price Aggregated volume
0 EUR 0.0000 EUR

e) Date of the transaction
2017-11-09; UTC+1

f) Place of the transaction
Outside a trading venue



10.11.2017 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Heidelberg Pharma AG
Schriesheimer Str. 101
68526 Ladenburg
Germany
Internet: www.heidelberg-pharma.com

 
End of News DGAP News Service

38785  10.11.2017 


© EQS 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on HEIDELBERG PHARMA AG
11/16 HEIDELBERG PHARMA : announces subscription price for new shares and conversion p..
11/13 HEIDELBERG PHARMA : announces results from research collaboration with Heidelber..
11/10 HEIDELBERG PHARMA AG : Notification and public disclosure of transactions by per..
11/10 HEIDELBERG PHARMA AG : Notification and public disclosure of transactions by per..
11/10 HEIDELBERG PHARMA AG : Notification and public disclosure of transactions by per..
11/10 HEIDELBERG PHARMA AG : Notification and public disclosure of transactions by per..
11/10 HEIDELBERG PHARMA AG : Notification and public disclosure of transactions by per..
11/10 HEIDELBERG PHARMA AG : Notification and public disclosure of transactions by per..
11/10 HEIDELBERG PHARMA AG : Notification and public disclosure of transactions by per..
11/10 HEIDELBERG PHARMA AG : Notification and public disclosure of transactions by per..
More news
News from SeekingAlpha
2016 Deal Flurry Shines Spotlight On Novel Multiple Myeloma Target
Financials (€)
Sales 2017 3,82 M
EBIT 2017 -10,0 M
Net income 2017 -11,0 M
Finance 2017 28,0 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 10,3x
EV / Sales 2018 10,3x
Capitalization 67,4 M
Chart HEIDELBERG PHARMA AG
Duration : Period :
Heidelberg Pharma AG Technical Analysis Chart | WL6 | DE000A11QVV0 | 4-Traders
Technical analysis trends HEIDELBERG PHARMA AG
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 4,22 €
Spread / Average Target 41%
EPS Revisions
Managers
NameTitle
Christof Hettich Chairman-Supervisory Board
Friedrich von Bohlen und Halbach Member-Supervisory Board
Georg F. Baur Deputy Chairman-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
HEIDELBERG PHARMA AG34.61%79
CELLTRION, INC.--.--%24 558
INCYTE CORPORATION5.19%22 258
IQVIA HOLDINGS INC37.36%22 074
LONZA GROUP59.52%19 560
ALNYLAM PHARMACEUTICALS, INC.240.57%12 538